M

    Myriad Genetics Inc (MYGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $3.22
    +0.06 (+1.90%)

    Market Cap: $302.25M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    -36.31%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.28 - $-0.15
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    5
    30d
    EPS Estimate Drift
    90d ago$0.07+132.5%
    60d ago$0.07+133.5%
    30d ago$0.07+133.5%
    7d ago$-0.18+17.3%
    Current$-0.21
    Revenue Consensus
    $191M
    Range$189M - $192M
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.43
    Range$-0.55 - $-0.24
    9 analysts
    Revenue Consensus
    $178M
    Range$173M - $184M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.43---
    Sep 26EST
    		-$-0.21---
    Jun 26
    		$-0.33$-0.08-312.50%Miss-760.0%
    Mar 26
    		$-0.09$-0.07-28.57%Miss-200.0%
    Dec 25
    		$0.04$-0.02+332.56%Beat+33.3%
    Sep 25
    		$-0.29$-0.01-2800.00%Miss-583.3%
    Jun 25
    		$0.05$-0.01+600.00%Beat+0.0%
    Mar 25
    		$-0.03$-0.05+40.00%Beat-200.0%
    Dec 24
    		$0.03$0.03-0.99%Miss-25.0%
    Sep 24
    		$0.06$0.02+200.00%Beat+300.0%
    Jun 24
    		$0.05$-0.01+600.00%Beat+162.5%
    Mar 24
    		$-0.01N/A+90.91%Beat+95.2%
    Dec 23
    		$0.04$0.01+300.00%Beat+133.3%
    Sep 23
    		$-0.03N/A+62.50%Beat+84.2%
    Jun 23
    		$-0.08$-0.09+11.11%Beat-300.0%
    Mar 23
    		$-0.21$-0.19-10.53%Miss-600.0%
    Dec 22
    		$-0.12$-0.16+25.00%Beat-500.0%
    Sep 22
    		$-0.19$-0.08-137.50%Miss-850.0%
    Jun 22
    		$0.04$0.02+100.00%Beat-66.7%
    Mar 22
    		$-0.03N/A+66.67%Beat+50.0%
    Dec 21
    		$-0.02$-0.02+0.00%Beat+83.3%
    Sep 21
    		$-0.02$-0.01-100.00%Miss+86.7%
    Jun 21
    		$0.12$-0.10+220.00%Beat+138.7%
    Mar 21
    		$-0.06N/A+60.00%Beat+25.0%
    Dec 20
    		$-0.12$-0.12+0.00%Beat-152.2%
    Sep 20
    		$-0.15$-0.30+50.00%Beat-287.5%
    Jun 20
    		$-0.31$-0.47+34.04%Beat-175.6%
    Mar 20
    		$-0.08$0.01-900.00%Miss-117.4%
    Dec 19
    		$0.23$0.29-20.69%Miss-39.5%
    Sep 19
    		$0.08N/A-74.19%Miss-81.4%
    Jun 19
    		$0.41$0.48-14.58%Miss+7.9%
    Mar 19
    		$0.46$0.43+6.98%Beat+48.4%
    Dec 18
    		$0.38$0.39-2.56%Miss+22.6%
    Sep 18
    		$0.43$0.31+38.71%Beat+65.4%
    Jun 18
    		$0.38$0.33+15.15%Beat+26.7%
    Mar 18
    		$0.31$0.27+14.81%Beat+14.8%
    Dec 17
    		$0.31$0.24+29.17%Beat+19.2%
    Sep 17
    		$0.26$0.21+23.81%Beat+13.0%
    Jun 17
    		$0.30$0.26+15.38%Beat-
    Mar 17
    		$0.27$0.24+12.50%Beat-
    Dec 16
    		$0.26$0.24+8.33%Beat-
    Sep 16
    		$0.23$0.25-8.00%Miss-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-4.81EV/EBITDA-23.47x
    Price/FCF-41.82xFCF Yield-2.39%
    Profitability
    Profit Margin-41.30%Operating Margin-21.40%
    ROE-23.50%ROIC-23.03%
    Financial Health
    Debt/Equity0.40xInterest Coverage-5.96x
    Current Ratio2.21xQuick Ratio1.98x
    Trading Statistics
    Beta1.64Avg Volume2.08M
    52-Week High$8.5952-Week Low$2.74

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.14
    SMA 20$3.16
    SMA 50$4.57
    SMA 200$5.13
    EMA 10$3.19
    EMA 20$3.42
    EMA 50$4.03
    EMA 200$5.07

    MACD

    Line: -0.37Signal: -0.46Hist: 0.09

    ADX

    ADX: 43.3+DI: 15.3-DI: 29.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down20.0
    PSAR$2.81

    Bollinger Bands

    Upper Band$3.34
    Lower Band$2.97
    %B Position1180%(Upper)
    Band Width0.67

    RSI (14-Day)

    Neutral
    39.0

    Momentum Oscillators

    Stoch %K74.9
    Stoch %D69.4
    Williams %R-16.3
    ROC (10d)5.6%
    Momentum0.17
    CCI (20d)32.3
    MFI (14d)40.4

    Volatility Measures

    ATR (14d)$0.24(7.4%)
    StdDev (20d)0.09
    Hist Vol59.8%(High)

    Volume Flow

    VWAP$3.17
    OBV-24.0M
    AD Line-53.0M
    CMF (20d)0.170

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.9x
    VWMA (20d)$3.15

    Pivot Points

    R3$3.35
    R2$3.27
    R1$3.22
    Pivot Point$3.14
    S1$3.09
    S2$3.01
    S3$2.96

    Advanced Oscillators

    TSI-31.86
    Ultimate Osc55.8
    KST-311.89

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$190.70M$200.40M$209.80M$205.70M$213.10M$195.90M$210.60M$213.30M$211.50M$202.20M$196.60M$191.90M
    Cost of Revenue$63.70M$62.80M$63.00M$61.90M$61.30M$61.70M$59.70M$63.50M$64.40M$64.60M$61.60M$57.60M
    Gross Profit$127.00M$137.60M$146.80M$143.80M$151.80M$134.20M$150.90M$149.80M$147.10M$137.60M$135.00M$134.30M
    Operating Expenses$165.90M$168.30M$152.50M$167.10M$481.00M$163.20M$190.00M$169.80M$183.60M$165.50M$166.40M$194.40M
    R&D$25.00M$27.10M$25.50M$28.20M$25.60M$27.50M$32.90M$28.50M$27.10M$24.90M$21.00M$24.00M
    SG&A$57.80M$62.20M$55.60M$67.90M$66.80M$66.50M$63.40M$69.20M$72.10M$71.20M$-144,800,000$136.10M
    Operating Income$-38,900,000$-30,700,000$-5,700,000$-23,300,000$-329,200,000$-29,000,000$-39,100,000$-20,000,000$-36,500,000$-27,900,000$-31,400,000$-60,100,000
    Interest Income$400,000$700,000$800,000$500,000$200,000$300,000$300,000$400,000$400,000$600,000$700,000$600,000
    Interest Expense$4.10M$4.10M$4.40M$3.80M$1.50M$800,000$700,000$800,000$800,000$500,000$900,000$1.00M
    Income Before Tax$-42,600,000$-34,100,000$-8,900,000$-26,200,000$-330,600,000$-29,400,000$-39,200,000$-21,200,000$-37,200,000$-25,900,000$-32,300,000$-61,200,000
    Income Tax Expense$600,000$0$-1,000,000$1.20M$-100,000$-29,300,000$3.30M$900,000$-500,000$100,000$-1,100,000$100,000
    Net Income$-43,200,000$-34,100,000$-7,900,000$-27,400,000$-330,500,000$-100,000$-42,500,000$-22,100,000$-36,700,000$-26,000,000$-31,200,000$-61,300,000
    EBITDA$-26,400,000$-18,200,000$7.30M$-10,300,000$-315,200,000$-14,500,000$-24,000,000$-5,200,000$-21,700,000$-10,300,000$-17,000,000$-46,700,000
    EBIT$-38,900,000$-30,700,000$-5,300,000$-22,900,000$-329,300,000$-28,900,000$-38,800,000$-20,800,000$-36,800,000$-26,000,000$-32,100,000$-60,800,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MYGN

    Government Contracts

    Gov Obligations (TTM)
    -$60344
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenues that were below Wall Street consensus and subsequently cut its full-year 2026 revenue guidance, citing reimbursement pressure and collections issues. The firm is encouraging affected shareholders to inquire about the securities investigation.

    ACCESS Newswire•8/22/26•
    Bearish

    Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

    Bronstein, Gewirtz & Grossman, LLC is investigating Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenue below Wall Street expectations and substantially cut its full-year 2026 revenue guidance, citing reimbursement pressure and other issues. Shareholders who purchased Myriad securities are encouraged to connect with the firm to assist with the investigation.

    ACCESS Newswire•8/20/26•
    Bearish

    Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

    Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price after the company reported lower-than-expected Q2 2026 revenue and substantially cut its full-year guidance. The firm is encouraging shareholders who purchased Myriad securities to join the investigation, citing potential claims related to the company's prior reiteration of higher revenue guidance just months before the revision.

    ACCESS Newswire•8/19/26•
    Bearish

    MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3.

    Stephens & Co. analyst Mason Carrico has maintained an "Equal-Weight" rating for Myriad Genetics (MYGN) but lowered its price target from $5.00 to $3.00, a 40% reduction. This reflects growing concerns about the company's financial performance, despite GuruFocus indicating the stock is 73.9% undervalued with a GF Value of $11.46 against its current price of $2.99. However, MYGN shows moderate overall performance with a GF Score of 55/100, hampered by unprofitability and a high forward P/E, suggesting caution for investors.

    GuruFocus•8/18/26•
    Bearish

    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenues that were below Wall Street consensus and subsequently cut its full-year 2026 revenue guidance, citing reimbursement pressures and other issues. The firm encourages investors who purchased Myriad securities to come forward and assist in the investigation.

    ACCESS Newswire•8/17/26•
    Bearish

    Frequently Asked Questions About MYGN

    Does MYGN pay dividends?
    Myriad Genetics Inc (MYGN) has a dividend payment track record. See the MYGN dividend history page for its current payment status, yield, and streaks.
    What is MYGN's market cap?
    Myriad Genetics Inc (MYGN) has a market capitalization of $302.25M with a current stock price of $3.22.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In